PF-4708671

Name: PF-4708671
Brand: Selleck Chemicals
SKU: S2163
Rating: 5 (36 reviews)

For research use only.

Licensed and Manufactured by Pfizer Catalog No.S2163

36 publications

CAS No. 1255517-76-0

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.

Selleck's PF-4708671 has been cited by 36 publications

Mol Cell, 2021, S1097-2765(21)00497-4

PubMed: 34245671 ( click the link to review the publication )

Cancers (Basel), 2021, 13(8)1909

PubMed: 33921066 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):108

PubMed: 33479203 ( click the link to review the publication )

Sci Rep, 2021, 11(1):13302

PubMed: 34172808 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3200

PubMed: 32581239 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):153

PubMed: 32843616 ( click the link to review the publication )

Life Sci, 2020, 265:118848

PubMed: 33278383 ( click the link to review the publication )

Viruses, 2020, 12(10)E1141

PubMed: 33050000 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 10.1007/s00018-020-03617-5

PubMed: 32804243 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202001183R

PubMed: 32686868 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Theranostics, 2019, 9(19):5464-5477

PubMed: 31534497 ( click the link to review the publication )

Oncogene, 2019, 38(35):6270-6282

PubMed: 31316145 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(18)E4424

PubMed: 31505737 ( click the link to review the publication )

Platelets, 2019, 30(2):241-250

PubMed: 29257917 ( click the link to review the publication )

Virulence, 2018, 9(1):83-98

PubMed: 28475412 ( click the link to review the publication )

Nutr Metab (Lond), 2018, 10.1186/s12986-018-0268-9

PubMed: 29743930 ( click the link to review the publication )

NPJ Breast Cancer, 2018, 4:36

PubMed: 30456298 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2553

PubMed: 28079897 ( click the link to review the publication )

Front Immunol, 2017, 7:685

PubMed: 28138329 ( click the link to review the publication )
Clin Exp Allergy, 2017, 47(4):488-498

PubMed: 28000949 ( click the link to review the publication )

Oncotarget, 2016, 7(32):52239-52254

PubMed: 27409169 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9163-74

PubMed: 26824321 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(3):799-809

PubMed: 25573956 ( click the link to review the publication )

J Immunol, 2015, 195(6):2529-39

PubMed: 26276876 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: 25561726 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Cell Immunol, 2015, 298(1-2):9-17

PubMed: 26302934 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

PLoS One, 2014, 9(2):e90388

PubMed: 24587347 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3145-58

PubMed: 24762669 ( click the link to review the publication )

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description

Targets

p70 S6K1 ^[1]
(Cell-free assay)

160 nM

In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BHT-101	M1ny[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfGN2w2UUN3ME2wMlgzODJ2IN88US=>	NITuN45USU6JRWK=
UACC-893	NUjkfnplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jUeGlEPTB;NT6xPVg5PiEQvF2=	MorSV2FPT0WU
A427	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nhbGlEPTB;NT63NlU3PyEQvF2=	NHLMUHFUSU6JRWK=
OCUB-M	MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\sOmlEPTB;Nj62OlExOiEQvF2=	NUnVfoNEW0GQR1XS
SW684	M3zDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoG2TWM2OD15LkWyNlY5KM7:TR?=	NGS1Ro1USU6JRWK=
SK-LMS-1	Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnBUoozUUN3ME25MlAyOzB{IN88US=>	NFL3c3NUSU6JRWK=
CP50-MEL-B	NVPyNHZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TR[WlEPTB;OT6zNFQyQSEQvF2=	NXnLO49DW0GQR1XS
NCI-H1651	NXTSS2t4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlG4TWM2OD1zMD6wNlc3KM7:TR?=	M2PpNnNCVkeHUh?=
ABC-1	MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDRbY9KSzVyPUGwMlExOzdizszN	NUjlNZFpW0GQR1XS
OE19	M3rJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLnTWM2OD1zMD6xO\|M{KM7:TR?=	NEDRPHNUSU6JRWK=
DSH1	Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnNTWM2OD1zMD64PFc6KM7:TR?=	NVKyfI1vW0GQR1XS
SW13	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnnSXZPUUN3ME2xNU46OzF7IN88US=>	MXvTRW5ITVJ?
MDA-MB-453	MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDkWnZKSzVyPUGyMlE3ODNizszN	NVmwbVNIW0GQR1XS
647-V	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjsTHREUUN3ME2xNk4{PTh{IN88US=>	NYTzZZpsW0GQR1XS
NCI-H2342	NVizb2F{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTKV5ZJUUN3ME2xNk4{QTl3IN88US=>	NXyyV2d6W0GQR1XS
LB2241-RCC	NVHTem1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHv2bIxKSzVyPUGyMlU4PzlizszN	M1jme3NCVkeHUh?=
UACC-257	NFW0d5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHLbmJxUUN3ME2xN{41PDV\|IN88US=>	M4HBbXNCVkeHUh?=
NCI-H661	NFjqbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfySGs1UUN3ME2xN{43PDR7IN88US=>	MmDJV2FPT0WU
FADU	M1LRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4WyU2lEPTB;MUOuOlk6OiEQvF2=	MW\TRW5ITVJ?
A2780	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXG1XoFCUUN3ME2xN{45ODRzIN88US=>	NVH1Um9oW0GQR1XS
NCI-H1793	NIHLS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnkcnFKSzVyPUG0MlQxQDVizszN	M{\CbnNCVkeHUh?=
TE-8	MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPMTWM2OD1zNT6zOFY2KM7:TR?=	MVnTRW5ITVJ?
HGC-27	NFXxNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH64Z\|ZKSzVyPUG2MlE3PDRizszN	MkXTV2FPT0WU
MMAC-SF	M{m2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlS3TWM2OD1zNz6zO\|I4KM7:TR?=	M{nvOXNCVkeHUh?=
Calu-6	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfFfVhKSzVyPUG4MlE2OTNizszN	MVnTRW5ITVJ?
HUTU-80	NXW1S5ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTF6LkO5OVkh\|ryP	MlWzV2FPT0WU
SAS	MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnGUGZKSzVyPUG4MlY1PTVizszN	NXHZR3Y{W0GQR1XS
IST-MES1	NWLOOIM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoG5TWM2OD1zOD62OVA5KM7:TR?=	NWHWZZk{W0GQR1XS
C3A	M1XWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXL5dmRRUUN3ME2xPE44QTF7IN88US=>	NX:wcWlYW0GQR1XS
ES3	MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTF6LkizOlQh\|ryP	Ml:5V2FPT0WU
HSC-2	MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTWZlh4UUN3ME2xPU43PTRzIN88US=>	NIXybopUSU6JRWK=
T47D	Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTXTWM2OD1{MD6xOFg2KM7:TR?=	MlfjV2FPT0WU
EW-7	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnPU3VMUUN3ME2yNE45PTh6IN88US=>	MmHyV2FPT0WU
LN-405	MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MomzTWM2OD1{MD64PVY2KM7:TR?=	MmC2V2FPT0WU
U031	M{jQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkCwTWM2OD1{MT60PFAzKM7:TR?=	M{CyN3NCVkeHUh?=
A549	NYL2dJdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4G0fmlEPTB;MkGuPFQ6OSEQvF2=	M{fS[XNCVkeHUh?=
RMG-I	MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVH2eoZXUUN3ME2yNk4zPjZ6IN88US=>	MmfVV2FPT0WU
BT-474	NVjUS4xlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTJ{Lk[1OVEh\|ryP	Mk\mV2FPT0WU
NB69	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{frbGlEPTB;MkOuNVUzKM7:TR?=	NHj4XIVUSU6JRWK=
NB7	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTJ2LkG4PEDPxE1?	NXy1WHh6W0GQR1XS
HCC1569	MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPuRldHUUN3ME2yOE43OTJ3IN88US=>	MX3TRW5ITVJ?
MEL-JUSO	NGD3VGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfPTWM2OD1{ND62PVA5KM7:TR?=	MkGyV2FPT0WU
MDA-MB-175-VII	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTJ3LkK1NVch\|ryP	MWLTRW5ITVJ?
HCC1419	NFOyW\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHe5dnlKSzVyPUK1MlYxODNizszN	M2L4Z3NCVkeHUh?=
Ca9-22	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTJ3Lk[0N\|Ih\|ryP	MV\TRW5ITVJ?
KGN	M1vIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYe1NHlZUUN3ME2yOU44PTR5IN88US=>	MlG4V2FPT0WU
LB373-MEL-D	Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTJ4LkG5N\|gh\|ryP	MonZV2FPT0WU
NCI-H1755	MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTJ4Lki4OFEh\|ryP	NHu4V4pUSU6JRWK=
D-423MG	MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vQWmlEPTB;MkeuNFcyPSEQvF2=	NEfISohUSU6JRWK=
DK-MG	NXy1RodqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTJ6Lke4OFYh\|ryP	MVrTRW5ITVJ?
NCI-H1623	M2\pS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml71TWM2OD1{OD64N\|QzKM7:TR?=	M2rIbnNCVkeHUh?=
KU-19-19	NGj5OHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTJ6Lkm5OUDPxE1?	MULTRW5ITVJ?
C-33-A	NH3BXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIC5cWxKSzVyPUK5MlIyQThizszN	NXrl[WFKW0GQR1XS
SCC-4	M{D6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Hj[WlEPTB;M{CuN\|M2PCEQvF2=	MmjPV2FPT0WU
MG-63	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWq0XVQ5UUN3ME2zNE42QTl2IN88US=>	NYC3UIdUW0GQR1XS
LNCaP-Clone-FGC	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTrV3hJUUN3ME2zNU41QTJzIN88US=>	M{KxfnNCVkeHUh?=
CAPAN-1	MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnMTWM2OD1\|MT61Nlg3KM7:TR?=	MoLoV2FPT0WU
GI-ME-N	Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3ITWM2OD1\|MT61N\|U{KM7:TR?=	MXjTRW5ITVJ?
RERF-LC-MS	NFvq[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrzOphbUUN3ME2zNk43PzR5IN88US=>	MkHqV2FPT0WU
KLE	NVH1UFlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmr1TWM2OD1\|Mz60N\|M1KM7:TR?=	MXLTRW5ITVJ?
KNS-81-FD	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXGzO2VKUUN3ME2zN{42ODB6IN88US=>	MoiyV2FPT0WU
DOK	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTXUm1VUUN3ME2zOE43PjF{IN88US=>	MVnTRW5ITVJ?
ACHN	NUjWVYRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3LeoxKSzVyPUO1MlE2QDhizszN	MkPWV2FPT0WU
KYSE-520	NHK5e4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\lTWM2OD1\|NT6yN\|YyKM7:TR?=	M1vMWXNCVkeHUh?=
SBC-5	MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXWTWM2OD1\|NT61NVE3KM7:TR?=	MXvTRW5ITVJ?
NCI-H28	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLwTWM2OD1\|NT62Olk2KM7:TR?=	MYPTRW5ITVJ?
ES7	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHezVXRKSzVyPUO2MlIzPDlizszN	M1HqNXNCVkeHUh?=
A172	Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTN4LkSxPFch\|ryP	MkLlV2FPT0WU
UM-UC-3	NHL5bHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTN5Lki3OFYh\|ryP	NF:0b5JUSU6JRWK=
LXF-289	MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmOzTWM2OD1\|OD6wNFQ4KM7:TR?=	NF7wcGhUSU6JRWK=
KP-4	NHG5R3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7qR\|FCUUN3ME2zPE41PzN7IN88US=>	Ml:xV2FPT0WU
TE-1	M1vB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULDephmUUN3ME2zPU43PTh7IN88US=>	M{G3R3NCVkeHUh?=
G-402	M4r1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPtUXZKSzVyPUSwMlA3OSEQvF2=	NX62ZXZKW0GQR1XS
786-0	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfMTWM2OD12MD65NFk3KM7:TR?=	M2rJVHNCVkeHUh?=
K5	M{TteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfOOZBKSzVyPUSxMlM3QDZizszN	NWi0ZnBiW0GQR1XS
SK-N-DZ	NInmbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPuTWM2OD12MT6zPFI{KM7:TR?=	NIrwc25USU6JRWK=
OVCAR-4	NUK3fGdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTsTWM2OD12MT63OVY5KM7:TR?=	MkPTV2FPT0WU
T84	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3uwUGlEPTB;NEKuNVI3OyEQvF2=	MUPTRW5ITVJ?
GCIY	M2PUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTR\|LkC4NFMh\|ryP	Mkf4V2FPT0WU
BB49-HNC	M1yzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXSTWM2OD12Mz6zN\|Q5KM7:TR?=	MUHTRW5ITVJ?
SNU-C2B	NFLLWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnYN\|RKSzVyPUSzMlY1OzZizszN	NFzzSnRUSU6JRWK=
TE-6	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrPOFZKSzVyPUSzMlg5QTRizszN	MUnTRW5ITVJ?
23132-87	MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXDSIQ1UUN3ME20OE4zQTd6IN88US=>	NWS0VY96W0GQR1XS
DMS-53	NVPUb49rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LMdWlEPTB;NESuN\|M5PCEQvF2=	NETJ[VdUSU6JRWK=
ONS-76	M4Lq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPVTWM2OD12ND63OlYyKM7:TR?=	MlezV2FPT0WU
DMS-273	M3XSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnFc3lKSzVyPUS0Mlk1OyEQvF2=	NVv4c\|FjW0GQR1XS
COLO-824	M1jobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzSflBKSzVyPUS1Mlg4PzVizszN	MVvTRW5ITVJ?
DMS-114	NVHuOFllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7KUVhKSzVyPUS1Mlg6OjdizszN	MVrTRW5ITVJ?
YKG-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTR4LkCzOVUh\|ryP	M2HCZXNCVkeHUh?=
RH-18	MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\2OFFKSzVyPUS2MlM4OzNizszN	MVTTRW5ITVJ?
NCI-H1355	NIfXZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTR4Lk[xPEDPxE1?	MnzoV2FPT0WU
NCI-H2170	NX:1UIdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPjTWM2OD12Nz63OVg1KM7:TR?=	NGq3RpdUSU6JRWK=
OC-314	M1n2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PzdWlEPTB;NEeuPFQ4QCEQvF2=	MnO3V2FPT0WU
NCI-H2030	M4DL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLvTWM2OD12Nz64PVA3KM7:TR?=	NGjGWpNUSU6JRWK=
22RV1	MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7VfWpKSzVyPUS3MlkxOTVizszN	MWTTRW5ITVJ?
G-401	NEK3[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULZNHd1UUN3ME20PE41PDF3IN88US=>	M1HvenNCVkeHUh?=
YAPC	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1yzT2lEPTB;NEmuPFA4OyEQvF2=	NFy1d5hUSU6JRWK=
SW1573	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnMW3pKSzVyPUWwMlI1OzVizszN	M4[4cnNCVkeHUh?=
COLO-792	M{nSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{S3OmlEPTB;NUCuOlI{PyEQvF2=	MYHTRW5ITVJ?
KNS-62	MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUn6bFNiUUN3ME21NE44PTB6IN88US=>	NX;vZZV7W0GQR1XS
NB5	NITRZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTVzLkS1NFkh\|ryP	NX;sSHA2W0GQR1XS
CP66-MEL	NIj6dFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPaTWM2OD13MT62OFA5KM7:TR?=	NHP0PYNUSU6JRWK=
CaR-1	NUfpTlNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PYdGlEPTB;NUKuNFYxPiEQvF2=	MUDTRW5ITVJ?
CAL-54	NV;xR5FET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYW2fW5MUUN3ME21Nk4yOTB{IN88US=>	M{HpOnNCVkeHUh?=
8305C	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4T0cGlEPTB;NUKuN\|E2KM7:TR?=	NGP5NWdUSU6JRWK=
Calu-3	MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfnSIp3UUN3ME21Nk4{PzN\|IN88US=>	M{jmTHNCVkeHUh?=
AU565	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoOyTWM2OD13Mj61OVA6KM7:TR?=	MkXSV2FPT0WU
CW-2	MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;HXIhXUUN3ME21Nk45PjV2IN88US=>	NHThZVFUSU6JRWK=
BEN	MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYO3W4loUUN3ME21N{44QDZ{IN88US=>	MXzTRW5ITVJ?
NCI-H1975	M4DJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTV\|Lki5OlYh\|ryP	NWXwcmhmW0GQR1XS
HCT-116	NGTJdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TVRWlEPTB;NUSuNFMzPyEQvF2=	MUXTRW5ITVJ?
SH-4	NXP2VndwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3u1R2lEPTB;NUSuNVM5KM7:TR?=	NVHVSZVRW0GQR1XS
NCI-H1693	NVvHUpZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTV2LkKxNFMh\|ryP	MUnTRW5ITVJ?
BPH-1	NG\ZUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HxSmlEPTB;NUWuNlg6OiEQvF2=	NVS2NGtkW0GQR1XS
CAMA-1	Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrDSlRXUUN3ME21OU45OTF4IN88US=>	NXHJUJlZW0GQR1XS
A388	NF;Sfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\XVmpXUUN3ME21Ok4xQTh3IN88US=>	M2LYVHNCVkeHUh?=
C2BBe1	NEi3W3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfrTWM2OD13Nj6yOlM1KM7:TR?=	MnjEV2FPT0WU
GAMG	MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3kSnR2UUN3ME21Ok42QTV3IN88US=>	MY\TRW5ITVJ?
MKN28	NX;qcoplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHKVopKSzVyPUW2MlgxOTNizszN	MlzvV2FPT0WU
VA-ES-BJ	MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HYdmlEPTB;NU[uPFc1PSEQvF2=	MXfTRW5ITVJ?
HuCCT1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTVTWM2OD13Nz6wOFkzKM7:TR?=	MX;TRW5ITVJ?
BFTC-905	NX;oZo1tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\vTWM2OD13Nz6yPFk5KM7:TR?=	M{fqc3NCVkeHUh?=
LS-123	M3;UbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfiTIlKSzVyPUW3MlU3PjhizszN	NXzCSpdFW0GQR1XS
LB996-RCC	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTV6LkCyPFch\|ryP	M3LDdnNCVkeHUh?=
NCI-H1048	NX\PUJZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPkTWM2OD13OD6yNVg5KM7:TR?=	NGm3bI1USU6JRWK=
COR-L105	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLPTWM2OD13OD63N\|M4KM7:TR?=	NVG0PGJ[W0GQR1XS
OVCAR-8	MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3kXWFKSzVyPUW5MlE4OTZizszN	NYfhfXkxW0GQR1XS
SK-N-FI	NH7UZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTV7LkOyNFch\|ryP	MojtV2FPT0WU
MES-SA	NETaNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3KXWpJUUN3ME21PU41PTB7IN88US=>	MmeyV2FPT0WU
SCC-9	NF;iR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jEOmlEPTB;NUmuOFc2OyEQvF2=	M{fUSHNCVkeHUh?=
EFO-27	NGnsU\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnHVlNKSzVyPUW5Mlk1OyEQvF2=	MYDTRW5ITVJ?
GT3TKB	Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HsSmlEPTB;NkCuOlA1QCEQvF2=	MnPaV2FPT0WU
HCC38	M1mwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;DUmlEPTB;NkGuOFM4QSEQvF2=	M3WwWHNCVkeHUh?=
MLMA	M4PJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPvOWtRUUN3ME22NU43OTZ\|IN88US=>	Mn;1V2FPT0WU
D-566MG	MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDicFA3UUN3ME22N{42OjJ2IN88US=>	MmTCV2FPT0WU
SF295	NFrqe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDmPIFKSzVyPU[zMlY3PTVizszN	MnfTV2FPT0WU
ES4	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnj2TWM2OD14ND60O\|E6KM7:TR?=	MYfTRW5ITVJ?
CAKI-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTZ2LkW3NlEh\|ryP	M3;NXHNCVkeHUh?=
OAW-28	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\IVYlKSzVyPU[0Mlk3PDdizszN	NEHpSWFUSU6JRWK=
NCI-H460	MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFr2VmNKSzVyPU[1MlA5QTdizszN	NHfZNHRUSU6JRWK=
JAR	NX\PdWJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTZ3LkW1NVYh\|ryP	NEXpc5hUSU6JRWK=
SNU-449	NHHGTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTZ3Lke2NVYh\|ryP	NGPmNG9USU6JRWK=
D-392MG	MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\lSmlEPTB;NkWuPVQ{PCEQvF2=	M3rrbHNCVkeHUh?=
EW-22	NGPQd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjtT4VKSzVyPU[2MlM6PSEQvF2=	NIDSS5RUSU6JRWK=
GCT	NYX3ZoJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTKTWM2OD14Nz6wOFQ{KM7:TR?=	NHTqdolUSU6JRWK=
NOS-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLIUoZKSzVyPU[3MlY5PjdizszN	NVzQPFl3W0GQR1XS
RH-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTZ6LkW1OVkh\|ryP	NFvQcmtUSU6JRWK=
HuH-7	NYTWUGhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DhOWlEPTB;NkmuNVAxOiEQvF2=	M37vT3NCVkeHUh?=
NUGC-3	MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXCTWM2OD15MD65OlQ1KM7:TR?=	NVX6dYlZW0GQR1XS
IST-SL1	NGrxeYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPBRWx5UUN3ME23NU4zOzJ2IN88US=>	NIj1cIlUSU6JRWK=
SHP-77	NX;SVpRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPoT2lKSzVyPUeyMlEyQSEQvF2=	NXvNTXBFW0GQR1XS
SW1116	M3zud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jLXWlEPTB;N{KuNVQxPyEQvF2=	MYjTRW5ITVJ?
LK-2	NGHsfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TKVWlEPTB;N{KuPFYyOiEQvF2=	MnTFV2FPT0WU
U-2-OS	NGTRTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTd\|LkG4Nlgh\|ryP	NFXsTpJUSU6JRWK=
KYSE-150	NIX0PZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIiyUVZKSzVyPUezMlYyOThizszN	MV\TRW5ITVJ?
U251	Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTd\|LkixOlgh\|ryP	M{\OeXNCVkeHUh?=
HT-1080	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTvTWM2OD15ND6yOVc1KM7:TR?=	MXrTRW5ITVJ?
NCI-H1437	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTd2Lk[zNlYh\|ryP	MnzaV2FPT0WU
HPAF-II	MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjqbXlKSzVyPUe0MlY1OTVizszN	MUnTRW5ITVJ?
Becker	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYT1bZR5UUN3ME23OU4yOTB3IN88US=>	NVHyUmEyW0GQR1XS
PANC-10-05	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlmxTWM2OD15NT6yPFY2KM7:TR?=	Mo\sV2FPT0WU
TYK-nu	NE\wS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTd3LkOxNFIh\|ryP	MVfTRW5ITVJ?
SKG-IIIa	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\Zd3VjUUN3ME23OU4{OzRzIN88US=>	NELteo9USU6JRWK=
NCI-H1993	Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rueGlEPTB;N{WuO\|M6PyEQvF2=	NVnIUJNwW0GQR1XS
S-117	MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXoTWM2OD15NT63OVUh\|ryP	MorwV2FPT0WU
HuO9	MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIH0cllKSzVyPUe2MlAxPDhizszN	NI\s[GpUSU6JRWK=
CAL-51	M3qy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHQbldKSzVyPUe2MlExODZizszN	NYfoVmxKW0GQR1XS
BT-20	NIrJPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTd4LkKxOlgh\|ryP	M17PSXNCVkeHUh?=
LB831-BLC	MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1H2eWlEPTB;N{[uN\|IyPyEQvF2=	M4OxcHNCVkeHUh?=
LB1047-RCC	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTd4Lke2NVkh\|ryP	MWnTRW5ITVJ?
ES8	MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHkTWM2OD15OD6wNFc{KM7:TR?=	NWLZelNGW0GQR1XS
UMC-11	NFTFOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1znc2lEPTB;N{iuNFg5PCEQvF2=	NHPqZXFUSU6JRWK=
NCI-H226	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nMNGlEPTB;N{iuNVMyPSEQvF2=	NIDENGhUSU6JRWK=
IGROV-1	M3LGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFflcXdKSzVyPUe4MlU2PSEQvF2=	MoDsV2FPT0WU
BHY	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7uTWM2OD15OT61PVYh\|ryP	NGrMc5NUSU6JRWK=
MKN45	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXpTWM2OD16MD6zNVc1KM7:TR?=	M1vpe3NCVkeHUh?=
IA-LM	M4TrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRThyLkO1NVEh\|ryP	MnroV2FPT0WU
WM-115	Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnj2TWM2OD16MT60NVE1KM7:TR?=	MkHEV2FPT0WU
VMRC-RCZ	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLkOYJVUUN3ME24NU41PDJ3IN88US=>	MX3TRW5ITVJ?
NCI-H2291	NYnj[2txT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXv2c4NRUUN3ME24NU43QDR{IN88US=>	M{jJZ3NCVkeHUh?=
MCF7	M17pdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTh\|LkK4PVch\|ryP	NXjsdIN{W0GQR1XS
639-V	M4nhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFmzOFZKSzVyPUi0MlYyOjlizszN	MWDTRW5ITVJ?
RT4	NV;PZ5d1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTh3LkK0NFMh\|ryP	M4HSZnNCVkeHUh?=
NCI-H2405	M1fjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zydWlEPTB;OEWuNlk6PyEQvF2=	NFrW[ZJUSU6JRWK=
CAL-33	NUj3WpZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PBN2lEPTB;OEWuOlMyPSEQvF2=	Mnf6V2FPT0WU
BT-549	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{POUGlEPTB;OEWuPVM5OiEQvF2=	MmmyV2FPT0WU
HT-1197	M1rx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorXTWM2OD16OD6xNFc4KM7:TR?=	MYfTRW5ITVJ?
G-361	NIqySIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTh6LkG0O\|Qh\|ryP	MWjTRW5ITVJ?
LS-411N	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\wdlJKSzVyPUi5MlM{QDhizszN	MYPTRW5ITVJ?
HT-144	NGjiWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTh7LkW5PVIh\|ryP	Mn\BV2FPT0WU
DJM-1	M2q3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXi5O3BuUUN3ME24PU45QDR3IN88US=>	MljwV2FPT0WU
CAL-12T	NGfafFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXiVIJKSzVyPUmwMlc5QTVizszN	NIS0bZdUSU6JRWK=
MKN7	NYHDe2Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDtfolbUUN3ME25NU4{PTVzIN88US=>	M4\nWHNCVkeHUh?=
HuP-T3	M1XENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTl4LkGwNFQh\|ryP	MWPTRW5ITVJ?
SK-MG-1	NULOeJR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXvdWh3UUN3ME25Ok4yOzR6IN88US=>	M13aV3NCVkeHUh?=
NCI-H2347	M2XGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DqVGlEPTB;OUiuNVA1OiEQvF2=	MnLXV2FPT0WU
SW872	MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml22TWM2OD1zMECuOFU3KM7:TR?=	MWnTRW5ITVJ?
COLO-829	M4DjdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLXXII1UUN3ME2xNFAvPTV\|IN88US=>	Mmj1V2FPT0WU
MC-IXC	NXHqcpJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fUSWlEPTB;MUCwMlYyPSEQvF2=	NHrx[JVUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-mTOR / mTOR / p-p70S6K / p70S6K ; PubMed: 30423811 Int J Mol Sci As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin. pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; PubMed: 28626016 J Neurosci Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times.	30423811 28626016
Growth inhibition assay	Cell viability; PubMed: 30423811 Int J Mol Sci Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, p < 0.01, and * p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red and * for SCC-4 and blue , * and *** for SCC-25).	30423811

Protocol

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Solubility (25°C)

In vitro	DMSO	30 mg/mL (76.84 mM)
	Ethanol	8 mg/mL (20.49 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-4708671 SDF

Molecular Weight	390.41
Formula	C₁₉H₂₁F₃N₆
CAS No.	1255517-76-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?
Answer:
The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

LY2584702 ^New

LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
LY2584702 Tosylate ^New

LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
BI-D1870

BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B. BI-D1870 exhibits anticancer attributes including the generation of reactive oxygen species (ROS) and increases in endoplasmic reticulum (ER) stress and autophagy.
Rapamycin (AY-22989)

Rapamycin (AY-22989, Rapamune, Sirolimus, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Everolimus (RAD001)

Everolimus (RAD001, SDZ-RAD) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671